Writing the Next Chapter in Precision Medicines

Discovering and developing the next generation of oncology precision medicines through:

Industry leaders with a proven track record of success

Building a broad pipeline of potentially best-in-class therapies

News

March 27, 2026
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
March 12, 2026
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
November 6, 2025
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
View All News